Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / PRVB - Provention Bio Is A Misunderstood Biotech With A Potential Quick Pathway To FDA Approval For Type 1 Diabetes Treatment


PRVB - Provention Bio Is A Misunderstood Biotech With A Potential Quick Pathway To FDA Approval For Type 1 Diabetes Treatment

Provention Bio (PRVB) is a speculative biotech that you should definitely look into for the coming months. That's because there are a lot of moving parts for this biotech that could provide significant upside for investors. That's because the goal is for the biotech to meet with the FDA in Q4 of 2019. This meeting will involve discussions on whether or not Prevention Bio can file a Biologics License Application ((BLA)) by the end of 2020. This will be for the "At Risk" patients for onset of Type 1 Diabetes. However, I believe

Read more ...

Stock Information

Company Name: Provention Bio Inc.
Stock Symbol: PRVB
Market: NASDAQ
Website: proventionbio.com

Menu

PRVB PRVB Quote PRVB Short PRVB News PRVB Articles PRVB Message Board
Get PRVB Alerts

News, Short Squeeze, Breakout and More Instantly...